NASDAQ$TECX
Tectonic Therapeutic Inc · Q2 2024 earnings
Q2 2024 earnings · · After market close · Investor relations
Briefing
Tectonic Therapeutic Inc reported its Q2 2024 financial results with a net loss of $12.7 million.
The company experienced a net loss of $12.7 million for the three months ended June 30, 2024, compared to $10.5 million in the prior year period. Research and development expenses decreased while general and administrative expenses increased due to merger-related activities. The company's cash position strengthened significantly following the merger and related financing.
- Net loss increased to $12.7 million from $10.5 million year-over-year primarily due to higher G&A expenses
- R&D expenses declined to $7.1 million as clinical supply production for TX45 was completed in 2023
- G&A expenses rose to $4.3 million driven by merger transaction costs and public company expenses
- Cash and cash equivalents increased to $185.1 million following the AVROBIO merger and subscription financing
Headline financials
Revenue & EPS history
Tectonic · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
-1.2%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+2.9%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+11.1%
Q4 2021
Best reaction
-20.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | +1.6% | — | — | |
| Q2 2024 | — | — | — | |
| Q4 2025 | -2.4% | +14.5% | +22.6% | |
| Q3 2025 | +1.5% | -0.7% | +4.9% | |
| Q1 2025 | -0.9% | +3.5% | -13.4% | |
| Q4 2024 | +1.0% | -11.8% | +11.0% | |
| Q3 2024 | -2.0% | +6.5% | +14.8% | |
| Q1 2024 | +0.0% | -0.8% | -7.0% | |
| Q4 2023 | +0.8% | -2.3% | -1.6% | |
| Q3 2023 | -9.9% | -13.2% | -7.2% | |
| Q2 2023 | +0.6% | -1.9% | +4.5% | |
| Q1 2023 | -4.5% | -4.5% | +82.1% | |
| Q4 2022 | -20.3% | -14.6% | -23.6% | |
| Q3 2022 | -1.5% | +12.1% | +19.7% | |
| Q2 2022 | +5.0% | +5.9% | -12.9% | |
| Q1 2022 | -7.3% | -1.2% | +30.5% | |
| Q4 2021 | +11.1% | +12.5% | -20.8% | |
| Q3 2021 | -1.0% | -3.8% | -40.7% | |
| Q2 2021 | +6.5% | -17.0% | -13.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro